-0.00029019152640744 -0.00058038305281488 -0.00261172373766696 -0.00207970593925327 -0.0014509576320372 0.000314374153608037 0.0025149932288643 0.00686786612497576
Thanks for submitting the form.
Stockreport

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and strategic announcements such as its collaboration with IDEAYA Biosciences might have countered market dips, aligning its trajectory with prevailing sector trends focused on innovation in healthcare. We've identified 4 risks with Gilead Sciences and understanding the impact should be part of your investment process. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent announcement of positive results from Gilead Sciences' Phase 3 ASCENT-04/KEYNOTE-D19 study in metastatic triple-negative breast cancer could potentially enhance their oncology revenue projections. This aligns well with recent efforts to expand in oncology and other therapeutic area [Read more]

IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Stockreport

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and strategic announcements such as its collaboration with IDEAYA Biosciences might have countered market dips, aligning its trajectory with prevailing sector trends focused on innovation in healthcare. We've identified 4 risks with Gilead Sciences and understanding the impact should be part of your investment process. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent announcement of positive results from Gilead Sciences' Phase 3 ASCENT-04/KEYNOTE-D19 study in metastatic triple-negative breast cancer could potentially enhance their oncology revenue projections. This aligns well with recent efforts to expand in oncology and other therapeutic area [Read more]

IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS